BEDFORD, Mass. — September 30, 2025 — Leads & Copy — Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced the pricing of its underwritten offering of 37,909,018 shares of common stock at $12.53 per share, projecting gross proceeds of approximately $475.0 million before deductions.
The offering, expected to close around October 1, 2025, will see all shares sold by the Company. BofA Securities, TD Cowen, and Piper Sandler & Co. are the joint book-running managers, with Baird and Raymond James as lead managers. Citizens Capital Markets and H.C. Wainwright & Co. are co-managers.
Net proceeds will fund the open-label extension study for AXPAXLI™ in wet age-related macular degeneration (wet AMD) patients, Phase 3 clinical trials of AXPAXLI for non-proliferative diabetic retinopathy (NPDR), infrastructure investments, pre-commercialization activities for AXPAXLI (if approved), and general corporate purposes.
The offering is made via an automatically effective shelf registration statement on Form S-3 filed with the SEC. The final prospectus supplement will be available on the SEC website.
This announcement is not an offer to sell or a solicitation of an offer to buy securities.
Ocular Therapeutix, Inc. is focused on redefining the retina experience with products like AXPAXLI™ and DEXTENZA®.
Bill Slattery, Vice President, Investor Relations, bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
